Results 231 to 240 of about 61,821 (357)

Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis. [PDF]

open access: yesMAbs
Sims GP   +26 more
europepmc   +1 more source

T cell targeting in cancer therapy [PDF]

open access: yes, 1991
Bolhuis, R.L.H. (Reinder)   +2 more
core   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

open access: yesFront Oncol
Oura M   +11 more
europepmc   +1 more source

Bone Formation and the Wnt Signaling Pathway. [PDF]

open access: yes, 2016
Baron, R., Gori, F., Superti-Furga, A.
core   +1 more source

Data from A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity

open access: gold
Baocun Li   +15 more
openalex   +1 more source

Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm

open access: yesInternal Medicine Journal, EarlyView.
Abstract Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated ...
S. Z. Xie   +14 more
wiley   +1 more source

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. [PDF]

open access: yesJ Immunother Cancer
Corona M   +26 more
europepmc   +1 more source

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies [PDF]

open access: bronze
Valentina Cardenas Castro   +28 more
openalex   +1 more source

Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps. [PDF]

open access: yesFront Oncol
Shao W   +8 more
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

open access: yesInternational Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy